HRP20221530T1 - Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke - Google Patents

Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke Download PDF

Info

Publication number
HRP20221530T1
HRP20221530T1 HRP20221530TT HRP20221530T HRP20221530T1 HR P20221530 T1 HRP20221530 T1 HR P20221530T1 HR P20221530T T HRP20221530T T HR P20221530TT HR P20221530 T HRP20221530 T HR P20221530T HR P20221530 T1 HRP20221530 T1 HR P20221530T1
Authority
HR
Croatia
Prior art keywords
cancer
hgdf
inhibitor
human
binds
Prior art date
Application number
HRP20221530TT
Other languages
English (en)
Inventor
Jörg WISCHHUSEN
Markus Haake
Reinhard DUMMER
Matthias MEHLING
Tina SCHÄFER
Martina SELLE
Original Assignee
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57121227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221530(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1517531.8A external-priority patent/GB201517531D0/en
Priority claimed from GBGB1607801.6A external-priority patent/GB201607801D0/en
Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg
Publication of HRP20221530T1 publication Critical patent/HRP20221530T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

1. Inhibitor hGDF-15 za uporabu u postupku za imunoterapiju raka, postupak je postupak liječenja solidnog raka u kombinaciji s blokatorom imunoloških kontrolnih točaka kod ljudskog pacijenata, naznačen time što se inhibitor hGDF-15 treba primijeniti na ljudskog pacijenata, pri čemu je inhibitor hGDF-15 monoklonsko antitijelo sposobno vezati se na hGDF-15, ili njegov dio koji se veže na hGDF-15, i pri čemu je blokator imunološke kontrolne točke odabran iz jedne ili više sljedećih skupina koje se sastoje od: i) inhibitora humanog PD-1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-1, ili njegov dio koji se veže na humani PD-1; i ii) inhibitora humanog PD-L1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-L1, ili njegov dio koji se veže na humani PD-L1.
2. Inhibitor hGDF-15 za uporabu prema zahtjevu 1, naznačen time što pacijent je pacijent koji ima razinu hGDF-15 u serumu od najmanje 1.2 ng/ml prije početka primjene inhibitora hGDF-15, pri čemu je pacijent poželjno pacijent koji ima razinu hGDF-15 u serumu od najmanje 1.5 ng/ml prije početka primjene inhibitora hGDF-15, i pri čemu je poželjnije pacijent je pacijent koji ima razinu hGDF-15 u serumu od najmanje 1.8 ng/ml prije početka primjene inhibitora hGDF-15; i/ili gdje je rak odabran iz skupine koju čine melanom, kolorektalni rak, rak prostate, rak glave i vrata, urotelni rak, rak želuca, rak gušterače, rak jetre, rak testisa, rak jajnika, rak endometrija, rak grlića maternice, rak mozga, rak dojke, rak želuca, karcinom bubrežnih stanica, Ewingov sarkom, rak pluća nemalih stanica i rak pluća malih stanica, pri čemu je rak poželjno odabran iz skupine koju čine melanom, kolorektalni rak, rak prostate, rak glave i rak vrata, urotelni rak, rak želuca, rak gušterače, rak jetre, rak testisa, rak jajnika, rak endometrija i rak grlića maternice, i gdje je rak poželjnije odabran iz skupine koju čine melanom, kolorektalni rak, rak prostate, rak glave i vrata, urotelni rak i rak želuca; i/ili pri čemu je rak odabran iz skupine koja se sastoji od melanoma, oralnog karcinoma skvamoznih stanica, kolorektalnog raka i raka prostate.
3. Inhibitor hGDF-15 za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je inhibitor monoklonsko antitijelo koje se može vezati na hGDF-15, ili njegov dio koji se veže na hGDF-15, pri čemu (i) vezanje je vezanje na konformacijski ili diskontinuirani epitop na hGDF-15, i pri čemu se konformacijski ili diskontinuirani epitop sastoji od aminokiselinskih sekvenci SEQ ID br.: 25 i SEQ ID br.: 26, i/ili pri čemu (ii) antitijelo ili njegov dio koji se veže na hGDF-15 sadrži varijabilnu domenu teškog lanca koja sadrži regiju CDR1 koja sadrži aminokiselinsku sekvencu SEQ ID NO: 3, regiju CDR2 koja sadrži aminokiselinsku sekvencu SEQ ID NO: 4 i CDR3 regiju koja sadrži aminokiselinsku sekvencu SEQ ID NO: 5, i pri čemu antitijelo ili njegov dio koji se veže na hGDF-15 sadrži varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiselinsku sekvencu SEQ ID NO: 6, CDR2 regiju koja sadrži aminokiselinsku sekvencu ser-ala-ser i CDR3 regiju koja sadrži aminokiselinsku sekvencu SEQ ID NO: 7.
4. Inhibitor hGDF-15 za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak je postupak za liječenje metastaza raka, i/ili pri čemu inhibitor hGDF-15 povećava postotak CD8+T-stanica u raku povećanjem adhezije CD8+T-stanica na endotelne stanice i time povećanje ulaska CD8+T-stanica iz krvotoka u rak.
5. Pripravak koji sadrži inhibitor hGDF-15 i blokator imunološke kontrolne točke, naznačen time što je inhibitor hGDF-15 monoklonsko antitijelo koje se može vezati za hGDF-15 ili njegov dio koji se veže na hGDF-15, i pri čemu je blokator imunološke kontrolne točke odabran iz jedne ili više sljedećih skupina koje se sastoje od: i) inhibitora humanog PD-1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-1, ili njegov dio koji se veže na humani PD-1; i ii) inhibitor humanog PD-L1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-L1, ili njegov dio koji se veže na humani PD-L1.
6. Pripravak prema zahtjevu 5, za uporabu u medicini.
7. Komplet koji sadrži inhibitor hGDF-15 i najmanje jedan blokator imunološke kontrolne točke, naznačen time što je inhibitor hGDF-15 monoklonsko antitijelo koje se može vezati za hGDF-15, ili njegov dio koji se veže na hGDF-15, i pri čemu je blokator imunološke kontrolne točke odabran je iz jedne ili više sljedećih skupina koje se sastoje od: i) inhibitora humanog PD-1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-1, ili njegov dio koji se veže na humani PD-1; i ii) inhibitor humanog PD-L1, inhibitor je monoklonsko antitijelo koje se može vezati na humani PD-L1, ili njegov dio koji se veže na humani PD-L1.
8. Komplet prema zahtjevu 7, naznačen time što se inhibitor hGDF-15 i jedan ili više ili svi blokatori imunoloških kontrolnih točaka nalaze u odvojenim spremnicima ili u jednom spremniku.
9. Pripravak za uporabu u medicini prema zahtjevu 6, ili komplet prema zahtjevu 7 ili 8, za uporabu u postupku za liječenje solidnog raka, naznačen time što je postupak poželjno postupak za imunoterapiju raka i pri čemu je poželjno da je rak definiran kao u zahtjevu 2.
10. Inhibitor hGDF-15 za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što uporaba je uporaba u kombinaciji s poliinozinskom:policitidilnom kiselinom, pri čemu kombinacija je kombinacija s poliinozinskom:policitidilnom kiselinom.
11. Inhibitor hGDF-15 za uporabu prema bilo kojem od zahtjeva 1-4 i 10, naznačen time što uporaba je uporaba u kombinaciji s imuno-stimulirajućim anti-humanimCD40 antitijelom, poželjno imuno-stimulirajućim monoklonskim anti-humanimCD40 antitijelom.
12. Kombinirani proizvod koji sadrži inhibitor hGDF-15 i bilo što od sljedećeg: a) poliinozinska:policitidilna kiselina; b) imuno-stimulirajuće anti-humanoCD40 antitijelo, poželjno imuno-stimulirajuće monoklonsko anti-humanoCD40 antitijelo; ili c) poliinozinska:policitidilna kiselina i imuno-stimulirajuće anti-humanoCD40 antitijelo, poželjno imuno-stimulirajuće monoklonsko anti-humanoCD40 antitijelo, za uporabu u postupku liječenja solidnog raka u ljudskom pacijentu, pri čemu kombinacija izborno sadrži blokator imunološke kontrolne točke, i pri čemu je inhibitor monoklonsko antitijelo sposobno vezati se na hGDF-15, ili njegov dio koji se veže na hGDF-15.
HRP20221530TT 2015-10-02 2016-09-30 Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke HRP20221530T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1517531.8A GB201517531D0 (en) 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
GBGB1607801.6A GB201607801D0 (en) 2016-04-29 2016-04-29 Combination therapy using inhibitors of human Growth and Differentiation Factor 15 (GDF-15) and immune checkpoint blockers
PCT/EP2016/073520 WO2017055613A2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EP16778750.6A EP3355919B1 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers

Publications (1)

Publication Number Publication Date
HRP20221530T1 true HRP20221530T1 (hr) 2023-03-17

Family

ID=57121227

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221530TT HRP20221530T1 (hr) 2015-10-02 2016-09-30 Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke

Country Status (22)

Country Link
US (2) US11464856B2 (hr)
EP (2) EP3355919B1 (hr)
JP (3) JP6925326B2 (hr)
KR (1) KR20180054868A (hr)
CN (2) CN108463246A (hr)
AU (2) AU2016333539B2 (hr)
BR (1) BR112018006218A2 (hr)
CA (1) CA3000293A1 (hr)
DK (1) DK3355919T3 (hr)
EA (1) EA201890850A1 (hr)
ES (1) ES2937167T3 (hr)
FI (1) FI3355919T3 (hr)
HK (1) HK1256067A1 (hr)
HR (1) HRP20221530T1 (hr)
HU (1) HUE060762T2 (hr)
IL (2) IL299478A (hr)
LT (1) LT3355919T (hr)
MD (1) MD3355919T2 (hr)
PL (1) PL3355919T3 (hr)
PT (1) PT3355919T (hr)
SI (1) SI3355919T1 (hr)
WO (1) WO2017055613A2 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910744T4 (tr) * 2012-09-26 2019-08-21 Univ Wuerzburg J Maximilians Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
WO2022101263A1 (en) * 2020-11-10 2022-05-19 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
CN112778419A (zh) * 2021-02-01 2021-05-11 重庆中元汇吉生物技术有限公司 抗ck-mb的抗体或其抗原结合部分及其应用
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2024052532A1 (en) 2022-09-08 2024-03-14 Catalym Gmbh Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543841A (ja) 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN102164959A (zh) 2008-09-29 2011-08-24 罗氏格黎卡特股份公司 针对人il17的抗体及其应用
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2012162561A2 (en) * 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
EP2807266B1 (en) * 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
TR201910744T4 (tr) 2012-09-26 2019-08-21 Univ Wuerzburg J Maximilians Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
DK2934584T3 (da) 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
EP4043580A1 (en) * 2013-03-15 2022-08-17 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
US20150104470A1 (en) * 2013-10-11 2015-04-16 Neil H. Riordan Immune modulation by peri-lymphatic or intra-lymphatic cell therapy
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
HUE047398T2 (hu) * 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére
WO2016049470A1 (en) 2014-09-25 2016-03-31 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
TWI803682B (zh) 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗－ｇｄｆ１５抗體、組成物及使用方法

Also Published As

Publication number Publication date
HUE060762T2 (hu) 2023-04-28
CA3000293A1 (en) 2017-04-06
MD3355919T2 (ro) 2023-02-28
CN117883572A (zh) 2024-04-16
JP6925326B2 (ja) 2021-08-25
EP4218809A2 (en) 2023-08-02
AU2016333539A1 (en) 2018-05-10
US20230093412A1 (en) 2023-03-23
AU2023202602A1 (en) 2023-05-18
BR112018006218A2 (pt) 2018-10-09
JP2021176891A (ja) 2021-11-11
JP2018534266A (ja) 2018-11-22
EP4218809A3 (en) 2023-08-09
KR20180054868A (ko) 2018-05-24
JP7443298B2 (ja) 2024-03-05
EP3355919B1 (en) 2022-12-07
PL3355919T3 (pl) 2023-03-20
EP3355919A2 (en) 2018-08-08
PT3355919T (pt) 2023-01-06
IL258393B2 (en) 2023-08-01
IL258393B1 (en) 2023-04-01
HK1256067A1 (zh) 2019-09-13
SI3355919T1 (sl) 2023-04-28
ES2937167T3 (es) 2023-03-24
AU2016333539B2 (en) 2023-02-23
WO2017055613A3 (en) 2017-07-06
US11464856B2 (en) 2022-10-11
EA201890850A1 (ru) 2018-09-28
WO2017055613A2 (en) 2017-04-06
JP2024054251A (ja) 2024-04-16
US20190160169A1 (en) 2019-05-30
IL258393A (en) 2018-05-31
DK3355919T3 (da) 2022-12-19
FI3355919T3 (fi) 2023-01-13
CN108463246A (zh) 2018-08-28
IL299478A (en) 2023-02-01
LT3355919T (lt) 2023-02-10

Similar Documents

Publication Publication Date Title
HRP20221530T1 (hr) Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
HRP20191335T1 (hr) Anti-egfrviii antitijela i njihove primjene
HRP20210440T1 (hr) Kombinirana terapija za rak
HRP20201404T1 (hr) Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
HRP20190749T1 (hr) Ljudska antitijela na pd-l1
IL278423B2 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
HRP20230060T1 (hr) Antitijela protiv ox40 i njihova primjena
MY191423A (en) Binding molecules specific for cd73 and uses thereof
IL291926B1 (en) FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
JP2018501197A5 (hr)
JP2017534633A5 (hr)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2016525117A5 (hr)
JP2017533912A5 (hr)
JP2020508317A5 (hr)
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
NZ631405A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer